To examine the efficacy and tolerability of calcipotriene combined with phototherapy or systemic therapies, compared with monotherapy, for the treatment of chronic plaque psoriasis.
For dichotomous outcomes, efficacy was estimated using the rate ratio (RR), defined as the proportion of patients achieving the outcome in the treatment group relative to the control group. Adverse events were estimated on the basis of the RR (or relative risk) and the rate difference. When there were no events in one group, the review's authors added 0.5 to each of the cells of the 2x2 table. In all cases, an intention to treat analysis was used. The Rothman method was used to estimate the 95% confidence intervals for the individual RRs and the rate difference (see Other Publications of Related Interest no.3).
For continuous outcomes, the percentage change in PASI from baseline was analysed using the weighted mean difference. This was defined as the difference between mean values in the treatment and control groups for individual trials, and the mean difference weighted for trial size for groups of trials (see Other Publications of Related Interest no.2). In estimating the weighted pooled difference in effect, the inverse of the squared sample variance of the difference in response was used as the weight.
Methods of synthesis
How were the studies combined? The method of DerSimonian and Laird (see Other Publications of Related Interest no.4), as implemented by Whitehead and Whitehead (see Other Publications of Related Interest no.5), was used to calculate pooled effect estimates and their corresponding 95% CIs. If there was no evidence of statistical heterogeneity, summary estimates of the effect from each trial were pooled using a fixed-effect model. A random-effects model was used if the P value was less than or equal to 0.05.
How were differences between studies investigated?
Heterogeneity between trials was investigated using chi-squared tests, where a P value equal to or less than 0.05 indicated significant heterogeneity.
Results of the review
Eleven RCTs were included in the review: 1 was a three-armed parallel group study, and 10 were two-armed head-tohead comparisons. [AC:Five of the latter were bi-lateral comparisons]. This represented a total of 756 patients randomised to treatment. Four trials were double-blind (388 participants), 2 were single-blind (177 participants) and 5 were open (191 participants).
When using the outcome of PASI, the antipsoriatic effects of acitretin, cyclosporine, and psoralen-UV-A phototherapy were enhanced by the addition of topical calcipotriene. This did not, however, translate into an increase in the number of patients who achieved at least marked improvement. At the end of treatment, the RRs for marked improvement or
